<DOC>
	<DOC>NCT00250679</DOC>
	<brief_summary>To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>This is a double-blind, double-dummy, multicenter, randomized, active-controlled, parallel group, outpatient, safety study to evaluate the long term safety of arformoterol in the treatment of subjects with COPD. Study participation will be over approximately 6 months. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Key Male and female subjects must be at least 35 years old at the time of consent Subjects must have a preestablished, documented primary clinical diagnosis of nonasthmatic COPD or are referred for diagnosis of nonasthmatic COPD Subjects must have a &gt;=15 packyear smoking history and a baseline breathlessness severity grade of &gt;=2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at Visits 1 and 2 Female subjects &lt;=65 years of age must have a negative serum pregnancy test, females of childbearing potential must be using an acceptable method of birth control Subjects must be in general good health. Key Exclusion criteria: Subjects with a history of asthma, with the exception of asthma diagnosed in childhood Subjects with a blood eosinophil count &gt;5% of total white blood cell count Subjects have had a febrile illness within 72 hours (3 days) before Screening Visit 1 Subjects with a chest xray that suggests a diagnosis other than COPD (e.g., diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions)</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>chronic bronchitis</keyword>
	<keyword>emphysema</keyword>
</DOC>